Literature DB >> 17728802

Risk of chronic kidney disease in hypertensive patients with other metabolic conditions.

D Weycker, G A Nichols, M O'Keeffe-Rosetti, J Edelsberg, G Vincze, Z M Khan, G Oster.   

Abstract

Using a retrospective cohort design and electronic medical records, we examined chronic kidney disease (CKD) risk over a 6-year period among hypertensive patients in relation to the presence of diabetes, hyperlipidaemia and/or high body mass index. After adjusting for age, sex, smoking status and baseline glomerular filtration rate (GFR), hypertensive patients without other metabolic risk factors had a relative risk of CKD (versus normotensive patients) of 2.0 (95% CI 1.8-2.2); hypertensive patients with other metabolic conditions had adjusted relative risks ranging from 2.4 to 2.6 for those without comorbid diabetes, and from 3.3 to 5.5 for those with comorbid diabetes. Our study thus confirms prior research demonstrating elevated CKD risk in hypertensive patients, and suggests that this risk varies substantially in relation to other metabolic conditions, especially diabetes.

Entities:  

Mesh:

Year:  2007        PMID: 17728802     DOI: 10.1038/sj.jhh.1002276

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  2 in total

1.  Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study.

Authors:  Asahi Hishida; Kenji Wakai; Mariko Naito; Shino Suma; Tae Sasakabe; Nobuyuki Hamajima; Satoyo Hosono; Mikako Horita; Tanvir Chowdhury Turin; Sadao Suzuki; Tara Sefanya Kairupan; Haruo Mikami; Keizo Ohnaka; Isao Watanabe; Hirokazu Uemura; Michiaki Kubo; Hideo Tanaka
Journal:  Lipids Health Dis       Date:  2014-10-14       Impact factor: 3.876

2.  Histone deacetylase inhibitor LMK235 attenuates vascular constriction and aortic remodelling in hypertension.

Authors:  Sin Young Choi; Hae Jin Kee; Simei Sun; Young Mi Seok; Yuhee Ryu; Gwi Ran Kim; Seung-Jung Kee; Marc Pflieger; Thomas Kurz; Matthias U Kassack; Myung Ho Jeong
Journal:  J Cell Mol Med       Date:  2019-02-07       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.